Receive the latest updates from Matrix Medical in real time to understand product information.
Arterial Network learned that recently Hangzhou Matrix Medical Technology Co., Ltd. (hereinafter referred to as "Matrix Medical") announced the completion of a Series A financing of tens of millions of yuan, which was jointly funded by Hetang Venture Capital and Anji Industrial Fund. The raised funds will continue to be used to support the clinical validation of the company's core products such as coronary artery remodeling catheters. At the same time, the company will further increase its R&D investment and launch more original medical device products around the treatment needs of clinical vascular diseases with the concept of "intervention without implantation".
Matrix Medical:
Matrix Medical was founded in 2021 and is headquartered in Hangzhou Future Science and Technology City. It is the first national high-tech enterprise in the industry to engage in intravascular photochemical crosslinking technology. The company adheres to the concept of "intervention without implantation" and focuses on the research and development and production of innovative medical devices in the field of vascular intervention. It is the first to create a Chinese solution based on the linkage of optics and vascular therapy, and has laid out a series of products, including coronary artery remodeling catheters (NVS series products), intracranial laser balloon dilation catheters (PBM series products), and hemostatic devices.
Against the backdrop of increasingly serious investment in the medical field, Matrix Medical is still highly favored by capital. Following the angel round financing of tens of millions of yuan in 2022 and the Pre-A round financing of tens of millions of yuan in 2023, Matrix Medical has received another round of funding from well-known institutions, fully demonstrating its strong strength and enormous potential in the field of vascular intervention.
At the same time, multiple product lines of Matrix Medical are rapidly advancing. In June 2024, the intracranial balloon dilation catheter was approved for NMPA certification; In January 2025, the coronary artery papillary balloon dilation catheter was successfully approved for NMPA certification, marking the beginning of a new chapter in commercial sales. In addition, the core products of coronary artery remodeling catheter and intracranial laser balloon dilation catheter have entered the clinical follow-up stage, and the arterial occlusion hemostatic device has been replaced. These series of achievements not only highlight the efficient capabilities of Matrix Medical in product development and registration, but also lay the foundation for its continuous research and development and deep layout in the market in the future.
In 2025, Matrix Medical will continue to focus on the field of vascular intervention, committed to continuously launching innovative medical device products with significant clinical value, promoting the development of vascular intervention technology, and providing safer and more effective solutions for the treatment of vascular disease patients.
Regarding the two core production lines:
1、NVS series products: Natural Vascular Scaffolding (NVS) therapy, is a new type of photochemical crosslinking technology that uses light-sensitive intelligent materials to activate and promote covalent binding between them and ECM protein amino acids in the blood vessel wall. It quickly constructs natural vascular micro scaffolds in damaged vascular tissue, thereby achieving in situ self-healing repair of blood vessels, reducing rebound, and leaving no foreign objects after retracting the balloon, truly realizing "no implantation after intervention". This technology can be widely applied in scenarios such as coronary arteries, peripheral arteries, nerves, and natural cavities, providing patients with a novel clinical treatment pathway for vascular injury repair.
2、PBM series products: Photobiomodulation (PBM) therapy, which utilizes the interaction between biocompatible tissue penetration light and intracellular chromophores to regulate cell and tissue interactions, has become a promising non tissue regeneration method. PBM directly acts on cells, promoting the adhesion and growth of endothelial cells, accelerating endometrial repair, and reducing smooth muscle cell proliferation.
Dr. Ji Peihong, founder of Matrix Medical, expressed his gratitude to Hetang Venture Capital and Anji Industrial Fund for their strong support. This is not only a recognition of our team, but also an affirmation of our product research and development direction. We will continue to uphold our original intention, further increase research and development investment, and launch more original products around the clinical treatment needs of vascular diseases. At the same time, we also thank our old shareholders Tai Yu Investment, Yisheng Shares, and our partners for their trust and support. Finally, I would like to express my gratitude to every hardworking and dedicated partner. Liu Huiqin, Managing Director of Hetang Venture Capital, stated that several products of Matrix Medical, including coronary artery remodeling catheters, have entered the clinical trial stage one after another. The team has demonstrated strong scientific research innovation and practical translation capabilities. Among them, Matrix Medical's coronary artery remodeling catheter, which is currently in clinical practice, is the first in the world to apply photochemical reactions to the treatment of coronary artery stenosis. This innovative and revolutionary product is highly anticipated by us.
Anji Industry Fund stated that in today's rapidly developing global medical technology, the prevention and treatment of cardiovascular and cerebrovascular diseases has always been a key focus of the medical field. The Matrix Medical team has continuously broken conventions in the field of cardiovascular intervention products, achieving key breakthroughs in multiple original research technologies, significantly improving the performance and safety of cardiovascular intervention products, and setting a benchmark for industry development. In the future, we will persist in being a "patient capital" and invest in industry funds to fully support Matrix Medical's work in product research and development, clinical promotion, production and manufacturing, and market expansion.
Institution Introduction - Hetang Venture Capital
Hetang Venture Capital was restructured and established in 2014 under the strategic background of promoting the transformation of scientific and technological achievements at Tsinghua University. It is a professional investment management institution mainly focused on early investment of technology innovative enterprises. Hetang Venture Capital focuses on major fields such as life sciences, medical devices, information technology, and modern manufacturing. It has long been dedicated to investing in innovative enterprises with core hard technologies, while also featuring incubation and investment of scientific and technological achievements from universities and top clinical experts in hospitals. Hetang Venture Capital currently manages a fund size of nearly 4 billion yuan, with a total of nearly 90 investment projects, supporting scientists and entrepreneurs with significant research discoveries and technological innovations to land their achievements, achieving "commercial transformation from 0 to 1", while always insisting on selecting high barrier "pioneering technologies" for early investment. With outstanding performance, Hetang Venture Capital has been awarded honors such as "Top 50 Early Stage Investment Institutions in China" by Rongzhong and "Top 50 Best Early Stage Venture Capital Institutions in China" by Zhongtong.
